Relative Value of the NSAIDs, Including COX-2 Inhibitors and Meloxicam

Curtiss, Frederic R.

doi:10.18553/jmcp.2006.12.3.265

Cited by 3 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Напри-мер, в США, по данным Управления по санитарному надзо-ру за качеством пищевых продуктов и медикаментов (Food and Drug Administration), рост продаж мелоксикама за 2005 г. увеличился в 2,18 раза [8].…”

Section: ф а р м а к о т е р а п и яunclassified

Prospects for using injectable meloxicam (Amelotex®) in patients with osteoarthrosis

Eliseyev¹,

Барскова²,

Владимиров³

2009

Modern Rheumatology Journal

View full text Add to dashboard Cite

Section: ф а р м а к о т е р а п и яunclassified

Prospects for using injectable meloxicam (Amelotex®) in patients with osteoarthrosis

Eliseyev¹,

Барскова²,

Владимиров³

2009

Modern Rheumatology Journal

View full text Add to dashboard Cite

“…When COX‐2 inhibitors were first introduced in the 1990s, they offered the potential for a decrease in these GI events (Shaw et al 2003). However, more recent studies have found that COX‐2 inhibitors do not reduce the risk of GI bleeding compared with NSAIDs as often as was originally believed (Stockl, Cyprien, and Chang 2005; Curtiss 2006). The effect of a PAR program for Celebrex ® (a COX‐2 inhibitor) on pharmacy and medical service utilization was studied in a Medicaid‐managed care organization in Oregon (Hartung et al 2004).…”

mentioning

confidence: 93%

Impact of Medicaid Prior Authorization Requirement for COX‐2 Inhibitor Drugs in Nebraska

Siracuse

Vuchetich

2007

Health Services Research

View full text Add to dashboard Cite

One year following implementation of the PAR, overall expenditures on COX-2 inhibitors for Nebraska Medicaid dropped 50 percent. The overall impact on pharmacy expenditures, including NSAIDs, pain relief medications, and gastroprotectants when necessary to relieve gastrointestinal (GI) side effects, for those recipients who switched from a COX-2 inhibitor to an NSAID or other pain relievers was a decline of approximately 35 percent. CONCLUSION AND IMPLICATIONS FOR STATE POLICY: PAR for COX-2 inhibitors successfully reduced Medicaid prescription expenditures. Recipients at high risk for GI side effects appropriately received COX-2 inhibitors. Recipients at low to moderate risk for GI side effects who were switched to NSAIDs or other pain relievers had lower overall prescription expenditures. Further research is needed to determine the impact of PAR on overall health outcomes and costs. In this study, rather than take a "one size fits all" approach to prescription drug cost-saving strategies, Medicaid policy makers understood that patient variation required accurate identification of disease severity to determine when equally efficacious low-cost alternatives were appropriate.

show abstract

Identifying early prescribers of Cycloxygenase-2 Inhibitors (COX-2s) in Nova Scotia, Canada: Considerations for targeted academic detailing

Groves

Schellinck

Sketris

et al. 2010

Research in Social and Administrative Pharmacy

View full text Add to dashboard Cite

Relative Value of the NSAIDs, Including COX-2 Inhibitors and Meloxicam

Cited by 3 publications

References 10 publications

Prospects for using injectable meloxicam (Amelotex®) in patients with osteoarthrosis

Prospects for using injectable meloxicam (Amelotex®) in patients with osteoarthrosis

Impact of Medicaid Prior Authorization Requirement for COX‐2 Inhibitor Drugs in Nebraska

Identifying early prescribers of Cycloxygenase-2 Inhibitors (COX-2s) in Nova Scotia, Canada: Considerations for targeted academic detailing

Contact Info

Product

Resources

About